Asterand to Acquire BioSeek | GenomeWeb

NEW YORK (GenomeWeb News) – UK-based Asterand today said that it will acquire BioSeek, a developer of cell-based assay systems, in a deal worth up to $14 million.

Asterand, which provides tissue-based services for drug discovery, said that the acquisition will provide it with highly complementary technologies, specifically BioSeek's BioMap platform and human cell-based assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.